AAPL322.01-6.20 (-1.89%) ▼|ABBV256.00-4.22 (-1.62%) ▼|ABT109.00+0.21 (+0.19%) ▲|ACN187.09-6.04 (-3.13%) ▼|ADBE268.59-17.16 (-6.01%) ▼|AMAT452.21+16.30 (+3.74%) ▲|AMD471.72+15.56 (+3.41%) ▲|AMGN436.90-7.22 (-1.63%) ▼|AMT175.81-1.94 (-1.09%) ▼|AMZN258.26-0.65 (-0.25%) ▼|AVGO356.28-0.88 (-0.25%) ▼|AXP326.71-3.11 (-0.94%) ▼|BA211.69+1.18 (+0.56%) ▲|BAC62.64-0.08 (-0.13%) ▼|BKNG193.63-1.50 (-0.77%) ▼|BLK1,121.80-4.35 (-0.39%) ▼|BMY66.65-1.44 (-2.11%) ▼|BNY165.23+0.90 (+0.55%) ▲|BRK-B505.99-2.14 (-0.42%) ▼|C137.72-0.42 (-0.30%) ▼|CAT810.20+10.06 (+1.26%) ▲|CL89.04-1.05 (-1.17%) ▼|CMCSA26.51-0.14 (-0.53%) ▼|COF219.19-1.31 (-0.59%) ▼|COP134.48-1.24 (-0.91%) ▼|COST917.72-7.70 (-0.83%) ▼|CRM260.49-3.94 (-1.49%) ▼|CSCO109.30+0.69 (+0.64%) ▲|CVS96.97-0.23 (-0.24%) ▼|CVX208.44-2.88 (-1.36%) ▼|DE695.87+1.46 (+0.21%) ▲|DHR207.45-3.58 (-1.70%) ▼|DIS105.76-1.40 (-1.31%) ▼|DUK120.26-1.14 (-0.94%) ▼|EMR152.49+2.28 (+1.51%) ▲|FDX321.96-2.36 (-0.73%) ▼|GD358.54-7.33 (-2.00%) ▼|GE336.44+2.96 (+0.89%) ▲|GEV941.39-0.46 (-0.05%) ▼|GILD150.41-0.81 (-0.54%) ▼|GM87.45+0.41 (+0.47%) ▲|GOOG336.11-2.97 (-0.87%) ▼|GOOGL339.36-2.90 (-0.85%) ▼|GS1,036.76-1.18 (-0.11%) ▼|HD321.52+3.45 (+1.08%) ▲|HON208.64+1.01 (+0.48%) ▲|IBM234.35-0.36 (-0.15%) ▼|INTC94.71+3.04 (+3.32%) ▲|INTU332.41-11.89 (-3.45%) ▼|ISRG366.92-2.92 (-0.79%) ▼|JNJ275.37-3.07 (-1.10%) ▼|JPM358.04-4.02 (-1.11%) ▼|KO88.04-0.77 (-0.87%) ▼|LIN478.46-3.74 (-0.77%) ▼|LLY1,142.99-16.61 (-1.43%) ▼|LMT524.92-8.03 (-1.51%) ▼|LOW205.05+3.15 (+1.56%) ▲|LRCX303.28+10.62 (+3.63%) ▲|MA581.09-4.62 (-0.79%) ▼|MCD256.62-3.01 (-1.16%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.32+1.22 (+1.31%) ▲|META615.44+4.76 (+0.78%) ▲|MMM168.37+0.06 (+0.03%) ▲|MO69.00-0.50 (-0.71%) ▼|MRK150.28-2.06 (-1.35%) ▼|MS217.02-0.13 (-0.06%) ▼|MSFT500.11-10.01 (-1.96%) ▼|MU1,003.46+45.30 (+4.73%) ▲|NEE83.42-0.64 (-0.76%) ▼|NFLX78.76-3.92 (-4.74%) ▼|NKE38.57-0.21 (-0.53%) ▼|NOW141.24-4.35 (-2.99%) ▼|NVDA229.89+1.44 (+0.63%) ▲|ORCL156.89+2.85 (+1.85%) ▲|PEP137.85-0.70 (-0.50%) ▼|PFE28.42-0.39 (-1.35%) ▼|PG146.32-0.61 (-0.41%) ▼|PLTR174.25-8.28 (-4.54%) ▼|PM182.65-3.52 (-1.89%) ▼|QCOM167.28-1.29 (-0.77%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.37-6.06 (-0.98%) ▼|TMUS182.89-5.13 (-2.73%) ▼|TSLA354.76-21.61 (-5.74%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|AAPL322.01-6.20 (-1.89%) ▼|ABBV256.00-4.22 (-1.62%) ▼|ABT109.00+0.21 (+0.19%) ▲|ACN187.09-6.04 (-3.13%) ▼|ADBE268.59-17.16 (-6.01%) ▼|AMAT452.21+16.30 (+3.74%) ▲|AMD471.72+15.56 (+3.41%) ▲|AMGN436.90-7.22 (-1.63%) ▼|AMT175.81-1.94 (-1.09%) ▼|AMZN258.26-0.65 (-0.25%) ▼|AVGO356.28-0.88 (-0.25%) ▼|AXP326.71-3.11 (-0.94%) ▼|BA211.69+1.18 (+0.56%) ▲|BAC62.64-0.08 (-0.13%) ▼|BKNG193.63-1.50 (-0.77%) ▼|BLK1,121.80-4.35 (-0.39%) ▼|BMY66.65-1.44 (-2.11%) ▼|BNY165.23+0.90 (+0.55%) ▲|BRK-B505.99-2.14 (-0.42%) ▼|C137.72-0.42 (-0.30%) ▼|CAT810.20+10.06 (+1.26%) ▲|CL89.04-1.05 (-1.17%) ▼|CMCSA26.51-0.14 (-0.53%) ▼|COF219.19-1.31 (-0.59%) ▼|COP134.48-1.24 (-0.91%) ▼|COST917.72-7.70 (-0.83%) ▼|CRM260.49-3.94 (-1.49%) ▼|CSCO109.30+0.69 (+0.64%) ▲|CVS96.97-0.23 (-0.24%) ▼|CVX208.44-2.88 (-1.36%) ▼|DE695.87+1.46 (+0.21%) ▲|DHR207.45-3.58 (-1.70%) ▼|DIS105.76-1.40 (-1.31%) ▼|DUK120.26-1.14 (-0.94%) ▼|EMR152.49+2.28 (+1.51%) ▲|FDX321.96-2.36 (-0.73%) ▼|GD358.54-7.33 (-2.00%) ▼|GE336.44+2.96 (+0.89%) ▲|GEV941.39-0.46 (-0.05%) ▼|GILD150.41-0.81 (-0.54%) ▼|GM87.45+0.41 (+0.47%) ▲|GOOG336.11-2.97 (-0.87%) ▼|GOOGL339.36-2.90 (-0.85%) ▼|GS1,036.76-1.18 (-0.11%) ▼|HD321.52+3.45 (+1.08%) ▲|HON208.64+1.01 (+0.48%) ▲|IBM234.35-0.36 (-0.15%) ▼|INTC94.71+3.04 (+3.32%) ▲|INTU332.41-11.89 (-3.45%) ▼|ISRG366.92-2.92 (-0.79%) ▼|JNJ275.37-3.07 (-1.10%) ▼|JPM358.04-4.02 (-1.11%) ▼|KO88.04-0.77 (-0.87%) ▼|LIN478.46-3.74 (-0.77%) ▼|LLY1,142.99-16.61 (-1.43%) ▼|LMT524.92-8.03 (-1.51%) ▼|LOW205.05+3.15 (+1.56%) ▲|LRCX303.28+10.62 (+3.63%) ▲|MA581.09-4.62 (-0.79%) ▼|MCD256.62-3.01 (-1.16%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.32+1.22 (+1.31%) ▲|META615.44+4.76 (+0.78%) ▲|MMM168.37+0.06 (+0.03%) ▲|MO69.00-0.50 (-0.71%) ▼|MRK150.28-2.06 (-1.35%) ▼|MS217.02-0.13 (-0.06%) ▼|MSFT500.11-10.01 (-1.96%) ▼|MU1,003.46+45.30 (+4.73%) ▲|NEE83.42-0.64 (-0.76%) ▼|NFLX78.76-3.92 (-4.74%) ▼|NKE38.57-0.21 (-0.53%) ▼|NOW141.24-4.35 (-2.99%) ▼|NVDA229.89+1.44 (+0.63%) ▲|ORCL156.89+2.85 (+1.85%) ▲|PEP137.85-0.70 (-0.50%) ▼|PFE28.42-0.39 (-1.35%) ▼|PG146.32-0.61 (-0.41%) ▼|PLTR174.25-8.28 (-4.54%) ▼|PM182.65-3.52 (-1.89%) ▼|QCOM167.28-1.29 (-0.77%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.37-6.06 (-0.98%) ▼|TMUS182.89-5.13 (-2.73%) ▼|TSLA354.76-21.61 (-5.74%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|
29.8 C
New York
Friday, September 4, 2026

Tag: tissue

newssourceFORcompanyinformationcontent1releasesmarket

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut. 
A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered

SHANGHAI, June 5, 2026 /PRNewswire/ -- On May 20, 2026, Aphranel® celebrated its first anniversary at the Waldorf Astoria Shanghai on the Bund, marking a...

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

London Specialist Dentists Announce the Use of Ozone Therapy in Periodontal Treatment and Dental Implants

LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- London Specialist Dentists has announced the use of medical-grade Ozone Therapy as part of its advanced approach to periodontal treatment, dental implant care, and minimally invasive gum therapy.

Mammotome Expands Access to Innovative Breast Biopsy Site Marker

Securing this CE mark expands access to the HydroMARK™ Plus markers across Europe, combining proprietary hydrogel technology with features designed to support marker stability...

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction

Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....

Looking to the Future from a Space-Based Lab

ISS National Lab highlights space R&D and growing low Earth orbit economy at ASCEND 2026KENNEDY SPACE CENTER, Fla., June 2, 2026 /PRNewswire/ -- The International...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTissue

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers